tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Andrew Tsai, 27 are a BUY (93.1%), 2 are a HOLD (6.9%).
Analyst Andrew Tsai, currently employed at JEFFERIES, carries an average stock price target met ratio of 36.67% that have a potential upside of 30.42% achieved within 146 days.
Andrew Tsai’s has documented 67 price targets and ratings displayed on 8 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on RLMD, Relmada Therapeutics at 17-Sep-2024.
Analyst best performing recommendations are on XENE (XENON PHARMACEUTICALS).
The best stock recommendation documented was for XENE (XENON PHARMACEUTICALS) at 8/30/2021. The price target of $28 was fulfilled within 35 days with a profit of $11.09 (65.58%) receiving and performance score of 18.74.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$19
$15.91 (514.89%)
$19
6 months ago
(20-Jun-2024)
0/3 (0%)
$16.71 (729.69%)
Buy
$5
$1.91 (61.81%)
$6
1 years 7 months 5 days ago
(15-May-2023)
0/3 (0%)
$2.13 (74.22%)
Buy
$10
$6.91 (223.62%)
$33
1 years 8 months 20 days ago
(30-Mar-2023)
0/2 (0%)
$7.54 (306.50%)
Buy
$3
$-0.09 (-2.91%)
$32
2 years 5 months 27 days ago
(23-Jun-2022)
2/5 (40%)
$0.25 (9.09%)
35
Buy
$36
2 years 5 months 28 days ago
(22-Jun-2022)
0/2 (0%)
$24.4 (210.34%)
Which stock is Andrew Tsai is most bullish on?
What Year was the first public recommendation made by Andrew Tsai?
